



PRESS RELEASE

Two Clinical Studies Featuring C2 Therapeutics' Cryoballoon Focal Ablation System to be Presented at DDW 2014

Redwood City, Calif. – May 2, 2014 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced that data from two clinical studies evaluating the therapeutic impact of its Coldplay Cryoballoon Focal Ablation System will be presented at Digestive Disease Week® (DDW®), on May 6th in Chicago, IL.

"The clinical studies at DDW evaluating the Coldplay Cryoballoon Focal Ablation System highlight our commitment to advancing the field of treatment for precursors to esophageal cancer," said Peter Garcia-Meza, President and CEO of C2 Therapeutics. "Treatment options to precursors such as Barrett's Esophagus need to be improved, and we believe the results of these trials will confirm the potential benefits of our technology for physicians around the world to help improve patient outcomes."

Schedule of Poster Presentations:

Monday, May 6 -- All posters are available from 8:00 a.m. - 5:00 p.m., Central Time Room -- ASGE Posters — Esophagus

Poster 1- TU1356:

Clinical evaluation of a new CryoBalloon Focal Ablation System for the elimination of Barrett's esophagus presented by Bas Weusten. The aim of the study was to assess the feasibility, safety, and dose-response of the newly Coldplay CryoBalloon Focal Ablation in patients with flat BE with or without dysplasia. Results on 33 patients are presented.

Investigators - D. Schölvinck, J. Bergman, C. Kestens, P. Siersema, F. Vleggaar, M. Canto, H. Cosby, J. Abrams, C. Lightdale, E. Tejada-Ramirez, S. DeMeester, C. Greene, B. Jobe, T. Hoppo, J. Peters, B. Weusten

Poster 2 - TU1385

Deep tissue ablation with little or no late fibrosis: animal and human data on esophageal cryoablation using the new Cryoballoon Focal Ablation System (TU1385) presented by Dirk Schölvinck. The aim of the study was to evaluate depth of tissue injury after CryoBalloon Focal Therapy. Results presented on 19 ablations in 5 animals and 4 ablations in 3 humans.

Investigators - D. Schölvinck, B. Weusten, G. Triadafilopoulos, T. Valli, S. Friedland



About Barrett's Esophagus

Barrett's Esophagus is a pre-cancerous condition of the esophagus commonly associated with gastric reflux disease (GERD) which affects as many as 60 million Americans. 3.5 MM people in the US have Barrett's and if left untreated, it can develop into adenocarcinoma, which is one of the most rapidly increasing and deadliest cancers in the United States. The risk of developing cancer with BE is 30 to 125 times higher than those without this condition. The 5-year survival rate is near 15%.

About C2 Therapeutics

C2 Therapeutics was founded in 2007 to address the limitations of current Barrett's Esophagus treatment options. Headquartered in Redwood City, California, C2 is a privately held company whose C2's Coldplay CryoBalloon Focal Ablation System sets a new standard for simplicity in ablation of Barrett's Esophagus. The device is a through-the-scope, highly compliant balloon catheter that is simultaneously inflated and cooled by an inert refrigerant delivered from a small disposable handheld unit. Operation is intuitive, fast, and cost-effective. The C2 Coldplay CryoBalloon Focal Ablation System eliminates the need for precise sizing, multiple deployment steps, and controller units.

For more information on C2 Therapeutics and its products, please visit <http://www.c2therapeutics.com/>.

Contact:

Peter Garcia-Meza, C2 Therapeutics

Ph: 650.521.5304